For several years it has been the case that Amgen Inc. (NASDAQ: AMGN) was considered a biotech though it had at least some of the same problems of Big Pharma players like Pfizer Inc. (NYSE: PFE)...
These are some of Tuesday’s top analyst upgrades, downgrades, and initiations seen from Wall Street research calls.Amgen Inc. (NASDAQ: AMGN) Cut to Market Perform at BMO. AutoNation Inc. (NYSE:...
Stock prices plunged this morning and spent most of the day trading way down. The DJIA hovered around -300 points for most of the day, while the NASDAQ was off around -50 points and the S&P 500...
It now costs about $1 billion to get a new drug to market, or, if a company is unlucky, $1 billion to fail to get the drug to market. Like the movie business, a drug company tries to develop that...
Crude oil is at $96.43, down 1.29%Gold is at $1,766, down 0.74%.Hong Kong’s Hang Seng closed down 1.44% to 18,226.Japan’s Nikkei closed lower by 0.32% to 8,348.The U.S. 10-year is at 1.95%, down...
Gilead Sciences Inc. (NASDAQ: GILD) is trading lower on news that it is spending some $11 billion to buy Pharmasset, Inc. (NASDAQ: VRUS).   What is interesting is that Pharmasset was valued only at...
Active traders and day traders have many stocks to choose from this Monday morning. We are tracking news and  moves in shares of OmniVision Technologies (NASDAQ: OVTI), Pharmasset, Inc. (NASDAQ:...
2011 has not exactly turned out the way many market pundits expected at the start of the year. The economy has slowed down to near-recession levels, the flight to safety has bond yields down to...